These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1335668)

  • 1. Cost-effectiveness analysis of hepatitis A prevention in travellers.
    Tormans G; Van Damme P; Van Doorslaer E
    Vaccine; 1992; 10 Suppl 1():S88-92. PubMed ID: 1335668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of vaccination against hepatitis A in travellers.
    Van Doorslaer E; Tormans G; Van Damme P
    J Med Virol; 1994 Dec; 44(4):463-9. PubMed ID: 7897383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effective analysis of hepatitis A prevention in Ireland.
    Rajan E; Shattock AG; Fielding JF
    Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries.
    Das A
    Hepatology; 1999 Feb; 29(2):548-52. PubMed ID: 9918934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
    Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
    Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization.
    Zaaijer HL; Leentvaar-Kuijpers A; Rotman H; Lelie PN
    J Med Virol; 1993 May; 40(1):22-7. PubMed ID: 8515245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who should receive hepatitis A vaccine? Considerations for the development of an immunization strategy.
    Margolis HS; Shapiro CN
    Vaccine; 1992; 10 Suppl 1():S85-7. PubMed ID: 1335667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of two strategies for preventing hepatitis A virus infection in Spanish travellers to developing countries.
    Bayas JM; González A; Vilella A; San-Martín M; Bertran MJ; Adell C
    Epidemiol Infect; 2001 Oct; 127(2):347-51. PubMed ID: 11693513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
    Reintjes R; Bosman A; de Zwart O
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on the control of hepatitis A by vaccination.
    Kane MA
    Vaccine; 1992; 10 Suppl 1():S93-6. PubMed ID: 1335670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic treatment regimens for the prevention of hepatitis A. Current concepts.
    Kendall BJ; Cooksley WG
    Drugs; 1991 Jun; 41(6):883-8. PubMed ID: 1715265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination strategies against hepatitis A in southern Europe.
    Franco E; Vitiello G
    Vaccine; 2003 Jan; 21(7-8):696-7. PubMed ID: 12531342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous active and passive immunization against hepatitis A studied in a population of travellers.
    Wagner G; Lavanchy D; Darioli R; Pécoud A; Brulein V; Safary A; Frei PC
    Vaccine; 1993; 11(10):1027-32. PubMed ID: 8212822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of vaccination against hepatitis A for frequent travellers.
    Fenn P; McGuire A; Gray A
    J Infect; 1998 Jan; 36(1):17-22. PubMed ID: 9515663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees.
    Purcell RH; D'Hondt E; Bradbury R; Emerson SU; Govindarajan S; Binn L
    Vaccine; 1992; 10 Suppl 1():S148-51. PubMed ID: 1335648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.
    Carlos F; Gómez JA; Anaya P; Romano-Mazzotti L
    Hum Vaccin Immunother; 2016; 12(1):52-63. PubMed ID: 26503702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].
    Pan XJ; Feng YM; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):862-6. PubMed ID: 22967346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses.
    Jakiche R; Borrego ME; Raisch DW; Gupchup GV; Pai MA; Jakiche A
    Am J Med Sci; 2007 Jan; 333(1):26-34. PubMed ID: 17220691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.